QUARTZ: Quality of Life After Radiotherapy and-or Steriods [ 2007 - 2012 ]

Research Grant

Researchers: Dr Tanya Holt (Principal investigator) ,  Prof Daniel Roos ,  Prof David Ball

Brief description Lung cancer is the commonest cause of cancer related death worldwide. In this group, one in four people will be diagnosed with brain metastases during their illness. This makes brain metastases a major health resource issue. For this group, the diagnosis of brain metastases is often associated with survival of less than 3 months. It is therefore important that this short survival period, which is often compromised by the effects of the disease, is not compromised further with the use of potentially toxic treatment. Whole Brain Radiotherapy (WBRT) is often used to treat these people. There is no current evidence to confirm that WBRT improves their quality of life. Most people with brain metastases routinely receive steroid medicine either as sole treatment or in addition to WBRT. Despite their potential side effects, steroids can control the symptoms of brain metastases and improve a person's quality of life. It is possible that the addition of WBRT adds nothing to steroids used alone or that only subgroups of these people benefit from WBRT. If these subgroups could be identified, treatment could be better tailored to the individual and minimise unnecessary hospital visits for these terminally ill patients. This could also potentially benefit the oncology community by translating into reduced radiotherapy waiting times. This is a unique, international collaborative study which aims to enroll 1000 people over a 3 year period from the UK, Australia and Canada .The main research question in this study is: Do the overall disadvantages of WBRT for lung cancer sufferers outweigh the advantages? It will be comparing the overall combination of quality and duration of survival in a) people receiving steroids and optimal palliative care alone to b) people receiving steroids, optimal palliative care and WBRT. The secondary research aims are to compare the two treatment groups in terms of symptoms experienced by the person and treatment side effects.

Funding Amount $AUD 63,000.00

Funding Scheme Targeted Calls

Notes Palliative Care Research